AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea Pharmaceuticals.
The Boston-based private biotech landed a huge $215 million series D financing round in March, which it is using toward a phase 2 trial of its oral purine nucleotide prodrug in people hospitalized with moderate cases of COVID-19.
That med, AT-527, works as a highly selective, orally administered direct acting antiviral, and is designed to inhibit the RNA polymerase enzyme, a key element in the replication machinery of RNA viruses. It’s hoped it can help beat out SARS-CoV-02, the virus causing COVID-19.